The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Published Date: 22 Apr 2024

Compared to chemotherapy, the ALK inhibitor lowered the risk of death or recurrence by 76%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

2.

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

3.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

4.

PSMA PET Beats MRI in Prostate Cancer Staging Study

5.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot